Peter B Gilbert

List of Publications by Year in Descending Order

162 papers	14,689 citations	44 h-index	120 g-index
173 ext. papers	20,281 ext. citations	10.8 avg, IF	6.44 L-index

#	Paper	IF	Citations
162	Innovative vaccine approaches-a Keystone Symposia report.. *Annals of the New York Academy of Sciences*, **2022**,	6.5	1
161	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science*, **2022** , 375, 43-50	33.3	116
160	Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention.. *PLoS Computational Biology*, **2022**, 18, e1010003	5	1
159	Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. *Human Immunology*, **2021**, 83, 53-53	2.3	0
158	Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. *Clinical Infectious Diseases*, **2021**, 73, 1540-1544	11.6	9
157	Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection. *PLoS Pathogens*, **2021**, 17, e1009406	7.6	7
156	Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines. *Clinical Infectious Diseases*, **2021**, 73, 1927-1939	11.6	7
155	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. *New England Journal of Medicine*, **2021**, 384, 1089-1100	59.2	36
154	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. *New England Journal of Medicine*, **2021**, 384, 1003-1014	59.2	77
153	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. *PLoS Pathogens*, **2021**, 17, e1009363	7.6	5
152	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. *Npj Vaccines*, **2021**, 6, 56	9.5	4
151	Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2021**, 87, 671-679	3.1	6
150	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (2020/01 - 2021/03) Using a Statistical Learning Strategy **2021**,		2
149	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. *Virus Evolution*, **2021**, 7, veab057	3.7	1
148	Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection. *Clinical Infectious Diseases*, **2021**,	11.6	2
147	Nonparametric variable importance assessment using machine learning techniques. *Biometrics*, **2021**, 77, 9-22	1.8	14
146	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. *Annals of Internal Medicine*, **2021**, 174, 221-228	8	47

145	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine*, **2021**, 384, 403-416	59.2	3691
144	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. *EBioMedicine*, **2021**, 64, 103203	8.8	7
143	Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine*, **2021**, 39, 4423-4428	4.1	277
142	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. *Annals of Internal Medicine*, **2021**, 174, 1118-1125	8	9
141	Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial **2021**,		46
140	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. *Viruses*, **2021**, 13,	6.2	3
139	A government-led effort to identify correlates of protection for COVID-19 vaccines. *Nature Medicine*, **2021**, 27, 1493-1494	50.5	7
138	Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation **2021**,		1
137	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *New England Journal of Medicine*, **2021**, 385, 1774-1785	59.2	105
136	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science*, **2021** , eab3435	33.3	84
135	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020-March 2021) Using a Statistical Learning Strategy.. *Viruses*, **2021**, 14,	6.2	3
134	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation.. *Scientific Reports*, **2021**, 11, 23921	4.9	10
133	Causal Isotonic Regression. *Journal of the Royal Statistical Society Series B: Statistical Methodology*, **2020**, 82, 719-747	3.9	3
132	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. *PLoS ONE*, **2020**, 15, e0234236	3.7	4
131	Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus. *Vaccine*, **2020**, 38, 3531-3536	4.1	5
130	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A□randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. *PLoS Medicine*, **2020**, 17, e1003038	11.6	14
129	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. *Scientific Reports*, **2020**, 10, 2093	4.9	10
128	A regularized estimation approach for case-cohort periodic follow-up studies with an application to HIV vaccine trials. *Biometrical Journal*, **2020**, 62, 1176-1191	1.5	5

127	Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2020**, 83, 434-439	3.1	1
126	Generating Survival Times Using Cox Proportional Hazards Models with Cyclic and Piecewise Time-Varying Covariates. *Statistics in Biosciences*, **2020**, 12, 1-16	1.5	1
125	Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. *MSphere*, **2020**, 5,	5	3
124	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. *PLoS Medicine*, **2020**, 17, e1003117	11.6	2
123	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. *PLoS ONE*, **2020**, 15, e0226803	3.7	10
122	RV144 HIV-1 vaccination impacts post-infection antibody responses. *PLoS Pathogens*, **2020**, 16, e1009107	7.6	3
121	Assessing trends in vaccine efficacy by pathogen genetic distance **2020**, 161, 164-175		
120	Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials **2020**,		13
119	Prospects for a safe COVID-19 vaccine. *Science Translational Medicine*, **2020**, 12,	17.5	99
118	Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials. *Biometrics*, **2020**,	1.8	5
117	Methods for comparing durability of immune responses between vaccine regimens in early-phase trials. *Statistical Methods in Medical Research*, **2020**, 29, 78-93	2.3	
116	Inference on treatment effect modification by biomarker response in a three-phase sampling design. *Biostatistics*, **2020**, 21, 545-560	3.7	6
115	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials **2020**, 16, e1007626		
114	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials **2020**, 16, e1007626		
113	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials **2020**, 16, e1007626		
112	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials **2020**, 16, e1007626		
111	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America **2020**, 15, e0234236		
110	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America **2020**, 15, e0234236		

109	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America **2020**, 15, e0234236		
108	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America **2020**, 15, e0234236		
107	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. *Journal of Virology*, **2019**, 93,	6.6	16
106	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. *Cell Host and Microbe*, **2019**, 26, 336-346.e3	23.4	43
105	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. *Science Translational Medicine*, **2019**, 11,	17.5	24
104	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. *Lancet HIV,the*, **2019**, 6, e737-e749	7.8	23
103	HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy. *BMC Infectious Diseases*, **2019**, 19, 453	4	11
102	Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial. *Journal of Virology*, **2019**, 93,	6.6	5
101	Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. *Lancet HIV,the*, **2019**, 6, e475-e482	7.8	13
100	Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. *PLoS Computational Biology*, **2019**, 15, e1006952	5	13
99	Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. *Nature Communications*, **2019**, 10, 863	17.4	17
98	Estimating and Testing Vaccine Sieve Effects Using Machine Learning. *Journal of the American Statistical Association*, **2019**, 114, 1038-1049	2.8	8
97	Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment. *Viruses*, **2019**, 11,	6.2	6
96	Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials. *Statistics in Medicine*, **2019**, 38, 4503-4518	2.3	5
95	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. *Journal of Clinical Investigation*, **2019**, 129, 4838-4849	15.9	55
94	Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. *American Journal of Tropical Medicine and Hygiene*, **2019**, 101, 164-179	3.2	4
93	Antigenic competition in CD4 T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. *Science Translational Medicine*, **2019**, 11,	17.5	8
92	Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs. *Statistical Communications in Infectious Diseases*, **2019**, 11,	0.7	2

91	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. *Frontiers in Immunology*, **2019**, 10, 2741	8.4	14
90	Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study. *Scientific Reports*, **2018**, 8, 6066	4.9	13
89	A joint model for mixed and truncated longitudinal data and survival data, with application to HIV vaccine studies. *Biostatistics*, **2018**, 19, 374-390	3.7	4
88	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. *Journal of Infectious Diseases*, **2018**, 217, 1280-1288	7	20
87	Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. *Journal of Infectious Diseases*, **2018**, 217, 742-753	7	54
86	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. *Human Vaccines and Immunotherapeutics*, **2018**, 14, 2116-2127	4.4	14
85	Estimation of the optimal surrogate based on a randomized trial. *Biometrics*, **2018**, 74, 1271-1281	1.8	9
84	Improved estimation of the cumulative incidence of rare outcomes. *Statistics in Medicine*, **2018**, 37, 280-293	2.3	10
83	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. *AIDS Research and Human Retroviruses*, **2018**, 34, 645-656	1.6	13
82	Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E8378-E8387	11.5	32
81	Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. *New England Journal of Medicine*, **2018**, 379, 327-340	59.2	368
80	Statistical Learning Methods to Determine Immune Correlates of Herpes Zoster in Vaccine Efficacy Trials. *Journal of Infectious Diseases*, **2018**, 218, S99-S101	7	7
79	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. *Lancet HIV,the*, **2018**, 5, e366-e378	7.8	62
78	Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. *Vaccine*, **2017**, 35, 1184-1193	4.1	6
77	Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. *MAbs*, **2017**, 9, 792-800	6.6	33
76	Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. *Journal of Infectious Diseases*, **2017**, 215, 1376-1385	7	43
75	SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials. *Bioinformatics*, **2017**, 33, 2386-2388	7.2	4
74	chngpt: threshold regression model estimation and inference. *BMC Bioinformatics*, **2017**, 18, 454	3.6	56

73	DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 T-Cell Responses by Interleukin-12 Plasmid DNA. *Vaccine Journal* , **2017**, 24,		24
72	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. *PLoS ONE*, **2017**, 12, e0176428	3.7	11
71	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. *Statistical Communications in Infectious Diseases*, **2017**, 9,	0.7	50
70	Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic Helical Structure. *PLoS ONE*, **2017**, 12, e0170530	3.7	10
69	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. *PLoS ONE*, **2017**, 12, e0179597	3.7	20
68	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. *PLoS ONE*, **2017**, 12, e0180720	3.7	42
67	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. *PLoS ONE*, **2017**, 12, e0185959	3.7	20
66	Modeling HIV vaccine trials of the future. *Current Opinion in HIV and AIDS*, **2016**, 11, 620-627	4.2	5
65	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. *Current Opinion in Virology*, **2016**, 17, 57-65	7.5	11
64	Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials. *PLoS ONE*, **2016**, 11, e0147812	3.7	30
63	FCGR2C Polymorphisms Associated with HIV-1 Vaccine Protection Are Linked to Altered Gene Expression of Fc-Receptors in Human B Cells. *PLoS ONE*, **2016**, 11, e0152425	3.7	10
62	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. *PLoS ONE*, **2016**, 11, e0161753	3.7	11
61	Power/sample size calculations for assessing correlates of risk in clinical efficacy trials. *Statistics in Medicine*, **2016**, 35, 3745-59	2.3	6
60	Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy. *Epidemiologic Methods*, **2016**, 5, 93-112	2.2	10
59	Search continues for a CMV vaccine for transplant recipients. *Lancet Haematology,the*, **2016**, 3, e58-9	14.6	3
58	Mark-specific hazard ratio model with missing multivariate marks. *Lifetime Data Analysis*, **2016**, 22, 606-25	1.3	5
57	Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. *PLoS Computational Biology*, **2015**, 11, e1003973	5	44
56	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. *Science Translational Medicine*, **2015**, 7, 296ra112	17.5	38

55	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. *New England Journal of Medicine*, **2015**, 373, 2025-2037	59.2	225
54	Immune correlates of vaccine protection against HIV-1 acquisition. *Science Translational Medicine*, **2015**, 7, 310rv7	17.5	142
53	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. *Nature Medicine*, **2015**, 21, 1139-41	50.5	29
52	Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition. *Journal of Causal Inference*, **2015**, 3, 157-175	1.9	10
51	Calibration weighted estimation of semiparametric transformation models for two-phase sampling. *Statistics in Medicine*, **2015**, 34, 1695-707	2.3	3
50	Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2015**, 64, 49-73	1.5	14
49	Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. *Journal of AIDS & Clinical Research*, **2015**, 6,	1	15
48	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. *PLoS ONE*, **2015**, 10, e0136626	3.7	15
47	COMPASS identifies T-cell subsets correlated with clinical outcomes. *Nature Biotechnology*, **2015**, 33, 610-6	44.5	165
46	Reply to Dunning. *Journal of Infectious Diseases*, **2015**, 212, 1521-3	7	
45	Use of placebos in Phase 1 preventive HIV vaccine clinical trials. *Vaccine*, **2015**, 33, 749-52	4.1	1
44	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. *PLoS ONE*, **2015**, 10, e0137666	3.7	22
43	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. *Lancet Infectious Diseases, The*, **2014**, 14, 388-96	25.5	80
42	Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trials. *Statistics in Medicine*, **2014**, 33, 901-17	2.3	5
41	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. *AIDS Research and Human Retroviruses*, **2014**, 30, A25-A26	1.6	
40	Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. *Journal of Virology*, **2014**, 88, 8242-55	6.6	44
39	Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-β secretion with increased HIV-1 infection risk: a cohort-based modeling study. *PLoS ONE*, **2014**, 9, e108631	3.7	17
38	Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. *EBioMedicine*, **2014**, 1, 37-45	8.8	40

37	Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. *Journal of Infectious Diseases*, **2014**, 210, 1573-81	7	68
36	Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. *Science Translational Medicine*, **2014**, 6, 228ra39	17.5	336
35	Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. *Vaccine Journal*, **2014**, 21, 1589-99		8
34	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. *Journal of Clinical Investigation*, **2014**, 124, 3879-90	15.9	86
33	Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. *PLoS ONE*, **2014**, 9, e87572	3.7	209
32	Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. *New England Journal of Medicine*, **2013**, 369, 2083-92	59.2	434
31	HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. *PLoS Pathogens*, **2013**, 9, e1003404	7.6	30
30	Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. *Journal of Infectious Diseases*, **2013**, 208, 1231-9	7	55
29	Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials. *Journal of the American Statistical Association*, **2013**, 108,	2.8	6
28	Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. *PLoS ONE*, **2013**, 8, e75665	3.7	189
27	Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. *Journal of Immunological Methods*, **2012**, 375, 57-67	2.5	51
26	Rejoinder to A Note on Two-Sample Tests for Comparing Intra-Individual Genetic Sequence Diversity Between Populations *Biometrics*, **2012**, 68, 1326-1326	1.8	
25	Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. *Lancet Infectious Diseases, The*, **2012**, 12, 531-7	25.5	162
24	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. *Nature*, **2012**, 490, 417-20	50.4	342
23	Immune-correlates analysis of an HIV-1 vaccine efficacy trial. *New England Journal of Medicine*, **2012** , 366, 1275-86	59.2	1400
22	Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. *Journal of Infectious Diseases*, **2012**, 206, 431-41	7	229
21	Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). *Journal of Infectious Diseases*, **2012**, 206, 258-66	7	161
20	Nomenclature for immune correlates of protection after vaccination. *Clinical Infectious Diseases*, **2012**, 54, 1615-7	11.6	216

19	The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. *AIDS Research and Human Retroviruses*, **2012**, 28, 1444-57	1.6	159
18	Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl. *International Journal of Biostatistics*, **2011**, 7, Article 36	1.3	18
17	Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. *Nature Medicine*, **2011**, 17, 366-71	50.5	186
16	Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. *Journal of Infectious Diseases*, **2011**, 203, 969-75	7	69
15	Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. *Journal of Infectious Diseases*, **2010**, 202, 595-605	7	101
14	Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. *Journal of Virology*, **2010**, 84, 1439-52	6.6	514
13	Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts. *Statistics in Medicine*, **2010**, 29, 1061-71	2.3	18
12	Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development. *Statistics in Biopharmaceutical Research*, **2009**, 1, 81-91	1.2	31
11	Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. *Lancet, The*, **2008**, 372, 1881-1893	40	1343
10	Genome scanning tests for comparing amino acid sequences between groups. *Biometrics*, **2008**, 64, 198-207	1.8	17
9	A framework for assessing immunological correlates of protection in vaccine trials. *Journal of Infectious Diseases*, **2007**, 196, 1304-12	7	161
8	Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. *Vaccine*, **2006**, 24, 6893-904	4.1	86
7	Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. *Journal of Virology*, **2005**, 79, 10108-25	6.6	939
6	Covariability of selected amino acid positions for HIV type 1 subtypes C and B. *AIDS Research and Human Retroviruses*, **2005**, 21, 1016-30	1.6	30
5	Simultaneous inferences on the contrast of two hazard functions with censored observations. *Biometrics*, **2002**, 58, 773-80	1.8	33
4	Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation. *Journal of Clinical Epidemiology*, **2001**, 54, 68-85	5.7	36
3	A general framework for inference on algorithm-agnostic variable importance. *Journal of the American Statistical Association*,1-38	2.8	2
2	Evaluating the Efficacy of COVID-19 Vaccines		1

List of Publications

1	Vaccines that prevent SARS-CoV-2 transmission may prevent or dampen a spring wave of COVID-19 cases and deaths in 2021	4